General Newsroom Hero 1920x480 (4:1)
Our Work

Firm Advises as RDIF, RCIF, and Middle Eastern Investors Acquire Stake in OBL Pharm

August 19, 2019
Transaction represents a milestone in the creation of a major Russian pharmaceuticals group.

Sistema PJSFC, a publicly traded diversified Russian holding company, has announced that a consortium of investors comprising the Russian Direct Investment Fund (RDIF), the Russia-China Investment Fund (RCIF) established by the RDIF and China Investment Corporation, and leading Middle Eastern funds (the Investment Consortium) have completed the acquisition of a minority stake in OBL Pharm for an amount exceeding RUB4 billion. 

Latham & Watkins advised Sistema in the transaction with a Moscow team led by corporate partner Olga Ponomarenko with associates Timur Bayramov, Oksana Uberwolf, and Vladimir Mikhailovsky.